Wegener Polyangiitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Wegener Polyangiitis - Pipeline Review, H1 2016

Wegener Polyangiitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Wegener Polyangiitis - Pipeline Review, H1 2016
Published Jun 15, 2016
60 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Wegener Polyangiitis - Pipeline Review, H1 2016, provides an overview of the Wegener Polyangiitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wegener Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wegener Polyangiitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wegener Polyangiitis
- The report reviews pipeline therapeutics for Wegener Polyangiitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Wegener Polyangiitis therapeutics and enlists all their major and minor projects
- The report assesses Wegener Polyangiitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wegener Polyangiitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Wegener Polyangiitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wegener Polyangiitis pipeline

  
Source:
Document ID
GMDHC8201IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Wegener Polyangiitis Overview61
Therapeutics Development71
  Pipeline Products for Wegener Polyangiitis Overview71
Wegener Polyangiitis Therapeutics under Development by Companies81
Wegener Polyangiitis Pipeline Products Glance94
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
  Unknown Stage Products121
Wegener Polyangiitis Products under Development by Companies131
Wegener Polyangiitis Companies Involved in Therapeutics Development149
  Bionovis SA141
  Bristol-Myers Squibb Company151
  ChemoCentryx, Inc.161
  Coherus BioSciences, Inc.171
  Genor BioPharma Co., Ltd.181
  GlaxoSmithKline Plc191
  Panacea Biotec Limited201
  Sandoz International GmbH211
  The International Biotechnology Center (IBC) Generium221
Wegener Polyangiitis Therapeutics Assessment239
  Assessment by Monotherapy Products231
  Assessment by Target242
  Assessment by Mechanism of Action262
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Drug Profiles3224
  abatacept Drug Profile325
  belimumab Drug Profile376
  CCX-168 Drug Profile435
  rituximab biosimilar Drug Profile482
  rituximab biosimilar Drug Profile501
  rituximab biosimilar Drug Profile511
  rituximab biosimilar Drug Profile521
  rituximab biosimilar Drug Profile531
  rituximab biosimilar Drug Profile541
  rituximab biosimilar Drug Profile551
Wegener Polyangiitis Dormant Projects561
Wegener Polyangiitis Discontinued Products571
Wegener Polyangiitis Product Development Milestones581
  Featured News &Press Releases581
    Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vascul...581
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Wegener Polyangiitis - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Wegener-Polyangiitis-Pipeline-Review-H1-2016-2088-15955>
  
APA:
Global Markets Direct - Market Research. (2016). Wegener Polyangiitis - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Wegener-Polyangiitis-Pipeline-Review-H1-2016-2088-15955>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.